DGAP-Adhoc

STADA Arzneimittel AG: Sales and earnings targets for 2014 at Group level met - crisis in the market region CIS/Eastern Europe requires impairments on goodwill as well as on further intangible assets in the expected amount of Euro 76.0 million before taxe

STADA Arzneimittel AG / Key word(s): Preliminary Results

19.02.2015 10:59

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Bad Vilbel, February 19, 2015 - The Executive Board of STADA Arzneimittel
AG has today, on February 19, 2015, published the preliminary figures for
financial year 2014, which have not yet been audited. Accordingly, Group
sales is expected to have risen by 3 percent to Euro 2,062.2 million
(previous year: Euro 2,003.9 million) (adjusted for currency and portfolio
effects: +1 percent). Reported EBITDA is expected to have increased by 9
percent to Euro 418.8 million (previous year: Euro 382.6 million). Adjusted
EBITDA is anticipated to have increased by 4 percent to Euro 431.9 million
(previous year: Euro 414.3 million). Overall, there were one-time special
effects in the expected amount of Euro 128.6 million before or Euro 121.6
million after taxes. They include impairments on goodwill in the expected
amount of Euro 54.0 million before and after taxes as well as on further
intangible assets in the expected amount of Euro 22.0 million before and
Euro 21.7 million after taxes as a result of the significantly changed
interest rate and currency environment as well as ongoing higher risks in
the market region CIS/Eastern Europe. In light of this, reported net income
is expected to have decreased by 47 percent to Euro 64.6 million (previous
year: Euro 121.4 million). Adjusted net income is anticipated to have
increased by 16 percent to Euro 186.2 million (previous year: Euro 160.6
million).

Due to the decreased net income reported, the STADA Executive Board
recommends that the Supervisory Board propose to the next Annual General
Meeting on June 3, 2015 an unchanged dividend of Euro 0.66 Euro per common
share for financial year 2014 (previous year: Euro 0.66). The resulting
total dividend payment of Euro 40.0 million (previous year: Euro 39.8
million) reflects a significantly higher distribution ratio than the
previous year at approximately 62 percent of net income reported.

Reported earnings per share are anticipated to have decreased to Euro 1.07
(previous year: Euro 2.04). Adjusted earnings per share are expected to
have increased to Euro 3.08 (previous year: Euro 2.70).

As of the balance sheet date, net debt is expected to amount to Euro